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ABSTRACT
Histone deacetylase 9 (HDAC9) is expressed in B cells, and its
overexpression has been observed in B-lymphoproliferative
disorders, including B-cell non-Hodgkin lymphoma (B-NHL). We
examined HDAC9 protein expression and copy number alterations in
primary B-NHL samples, identifying high HDAC9 expression among
various lymphoma entities and HDAC9 copy number gains in 50%
of diffuse large B-cell lymphoma (DLBCL). To study the role of
HDAC9 in lymphomagenesis, we generated a genetically engineered
mouse (GEM) model that constitutively expressed an HDAC9
transgene throughout B-cell development under the control of
the immunoglobulin heavy chain (IgH) enhancer (Eμ). Here, we
report that the Eμ-HDAC9 GEM model develops splenic marginal
zone lymphoma and lymphoproliferative disease (LPD) with
progression towards aggressive DLBCL, with gene expression
profiling supporting a germinal center cell origin, as is also seen in
human B-NHL tumors. Analysis of Eμ-HDAC9 tumors suggested that
HDAC9 might contribute to lymphomagenesis by altering pathways
involved in growth and survival, as well as modulating BCL6 activity
and p53 tumor suppressor function. Epigenetic modifications play an
important role in the germinal center response, and deregulation of
the B-cell epigenome as a consequence of mutations and other
genomic aberrations are being increasingly recognized as important
steps in the pathogenesis of a variety of B-cell lymphomas. A
thorough mechanistic understanding of these alterations will inform
the use of targeted therapies for these malignancies. These findings
strongly suggest a role for HDAC9 in B-NHL and establish a novel
GEM model for the study of lymphomagenesis and, potentially,
preclinical testing of therapeutic approaches based on histone
deacetylase inhibitors.
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INTRODUCTION
Non-Hodgkin lymphoma (NHL) are a heterogeneous group of
cancers of B, T or natural-killer cells, and constitute 4-5% of all
cancers (Ferlay et al., 2013; Siegel et al., 2015), with diffuse large
B-cell lymphoma (DLBCL) being the most common subtype,
accounting for 31% of all adult NHLs (Martelli et al., 2013).
Overall, approximately five cases of NHL per 100,000 individuals
are identified annually (rising to 12 per 100,000 in North America),
with incidence increasing, especially in developed countries.
Similarly, NHL is the 11th most common cause of cancer death
worldwide, resulting in around 200,000 deaths in 2012. Despite
improvements in 5-year relative survival rates to 70% over the last
four decades (largely due to the use of antibodies and antibody–
drug conjugates directed against cell-surface antigens), patients
with relapsed or refractory disease continue to have poor outcomes
(Ansell, 2015; Grover and Park, 2015). New approaches are
therefore required in NHLs, and therapeutic targeting of epigenetic
modifiers, including histone deacetylases (HDACs), holds great
promise (Hassler et al., 2013).
HDACs catalyze deacetylation of acetylated lysine residues on
histones, and are also being found to act on a growing number of
non-histone proteins (Haberland et al., 2009; Yang and Seto, 2008).
As such, the functional interaction networks of HDACs encompass
many biological and cellular processes beyond chromatin
modification and gene regulation. In humans, there are 11
canonical HDACs grouped into three major classes: class I
comprises HDACs 1, 2, 3 and 8; class II comprises HDACs 4, 5,
6, 7, 9 and 10; and class IV is represented by HDAC11. HDAC9,
alongside HDACs 4, 5 and 7, forms the class IIa subfamily, and
these proteins are key transcriptional co-regulators in development
and differentiation (Martin et al., 2009). Mutation or aberrant
expression of HDAC9 has been implicated in diverse conditions,
including ischemic stroke, schizophrenia and obesity (Bellenguez
et al., 2012; Chatterjee et al., 2014; Lang et al., 2012), and also as a
maker of poor outcome in cancer (Milde et al., 2010; Moreno et al.,
2010). HDAC9, which is subject to complex regulation via
differential promoter usage and alternative splicing, is
preferentially expressed in the lymphoid lineage within the
hematopoietic system (Petrie et al., 2003). HDAC9 is highly
expressed in B-lymphoproliferative disorders, including in B-cell
non-Hodgkin lymphoma (B-NHL) cell lines and patient samples,
suggesting that its deregulation might lead to abnormal B-cell
proliferation (Petrie et al., 2003; Sun et al., 2011). These findings are
supported by the recurrent amplification of the HDAC9 locus (chr.
7p21.1) in B-NHL (Bea et al., 2005; Bentz et al., 1999, 1996;Monni
et al., 1996; Rubio-Moscardo et al., 2005; Tagawa et al., 2005).
Additionally, a number of HDAC inhibitors have been shown to
induce cell death in B-NHL cells (Haery et al., 2015; Lemoine and
Younes, 2010). Although several in vivo mouse models examiningReceived 26 January 2016; Accepted 21 October 2016
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the biological functions of the class I and II HDACs are available
(Witt et al., 2009), a role for HDAC9 or other family members in B-
NHL has not been examined in vivo. The study of Hdac9–/–
knockout mice has, however, highlighted HDAC9 as an important
factor in inhibiting the generation and function of regulatory T (Treg)
cells (Tao et al., 2007; Yan et al., 2011).
Underlining a potential role in B-NHL, HDAC9 interacts with
BCL6 (Basso et al., 2010; Miles et al., 2005; Petrie et al., 2003), a
transcriptional repressor that is crucial for germinal center (GC)
formation (Basso and Dalla-Favera, 2012). Transgenic mice that
constitutively express BCL6 in B cells develop a lymphoproliferative
syndrome that culminates with the development of B-NHL (Cattoretti
et al., 2005). BCL6 directly recruits class-II HDACs through its zinc-
finger domain (Lemercier et al., 2002), and its transcriptional targets
in GC B cells include TP53, thus modulating DNA-damage-induced
apoptotic responses (Phan and Dalla-Favera, 2004). Evidence for a
major role for defective acetylation in the pathogenesis of B-NHL is
supported by the frequent occurrence of structural alterations
inactivating CREBBP and EP300, genes encoding two highly
related histone acetyltransferases (HATs) and non-HATs
(Pasqualucci and Dalla-Favera, 2015; Pasqualucci et al., 2011).
These mutations lead to aberrant activation and deactivation,
respectively, of BCL6 and p53 (Pasqualucci et al., 2011), and we
hypothesized that aberrant HDAC9 expression could also interfere
with p53 and/or BCL6. We therefore sought to characterize HDAC9
expression in human B-cell lymphomas and establish whether
aberrant expression can drive B-cell lymphoma in a genetically
engineered mouse (GEM)model. Here, we report the development of
a GEM inwhich anHDAC9 transgenewas constitutively expressed in
B cells under the control of the immunoglobulin heavy chain (Eμ)
enhancer (Eµ-HDAC9). Eµ-HDAC9 mice developed B-
lymphoproliferative disorders with progression towards B-NHL.
This is consistent with the hypothesis that deregulated protein
acetylation plays a pathological role in B-NHL, and provides a model
for preclinical evaluation of HDAC inhibitors (HDACIs).
RESULTS
Within the immune system, a role for HDAC9 in the control of Treg
cell function has previously been described (Beier et al., 2012; de
Zoeten et al., 2010; Parra, 2015; Tao et al., 2007), and we found that,
in normal human mature B cells, HDAC9 mRNA expression is
significantly upregulated in the GC (Petrie et al., 2003) (Fig. 1A).
HDAC9 protein is detected in a subset of GC cells, where it is co-
expressed with BCL6 (Fig. 1A), as well as in a subset of lymphoid
cells in the mantle zone and paracortex (Klein et al., 2003) (Fig. 1B).
High HDAC9 gene expression in B-lymphoproliferative disorders,
including B-NHL cell lines and patient samples, has pointed to a
potential role in these diseases (Petrie et al., 2003; Sun et al., 2011).
In line with these findings, we detected high HDAC9 protein levels
among various lymphoma entities, including DLBCL (n=34),
marginal zone lymphoma (MZL) (n=5), follicular lymphoma (FL)
(n=9), classical Hodgkin lymphoma (CHL) (n=3) and mantle cell
lymphoma (MCL) (n=6). Highest levels of HDAC9 expression were
observed in the most aggressive lymphomas, such as DLBCL (both
GC and non-GC subtypes) and MCL (77% and 83%, respectively,
P=1.0, Fisher’s exact test). In contrast, low-grade B-cell
lymphomas, as well as CHL, showed low HDAC9 expression in
tumor cells when nuclear intensity was compared with that of
adenocarcinoma cells as a positive control (P=0.004, Fisher’s exact
test) (Fig. 1C). In addition to high HDAC9 expression, frequent
amplification of the HDAC9 locus (chr. 7p21.1) has been observed
in B-NHL (Bea et al., 2005) and, consistent with these results, we
found copy number gains of HDAC9, including high-level
amplifications, in 46.3% (25/54) of DLBCL patients (Fig. S1). A
total of 46% (13/28) of samples with HDAC9 copy number gains
presented trisomy 7 (Fig. S1A), whereas 43% (12/28) of cases
reported with smaller regions of amplification within the
chromosome that contained the HDAC9 gene (Fig. S1B). Here,
one case displayed a specific amplification of HDAC9 (18,409,840-
18,605,177 bp) (Fig. S1C, Table S1).
Although several in vivomouse models examining the biological
functions of the class I and II HDACs are available (Parra, 2015), a
role for HDAC9 or other class-IIa family members in B-NHL has
never been examined in vivo. We therefore expressed a human
HDAC9 transgene (HDAC9TG) in the B-cell compartment from an
early stage of B-cell development under the control of the
immunoglobulin heavy chain (IgH) enhancer (Eμ) (Fig. S2A). We
generated three independent transgenic lines (designated as 1468,
1469 and 1839) (Fig. S2B) and monitored a total of 124 mice (78
Eµ-HDAC9 and 46 wild type) for tumor formation and overall
survival. We found expression of theHDAC9TG in the bone marrow
and spleen but not in the liver (Fig. 2A). We detected expression of
HDAC9TG throughout all B-cell stages in the bone marrow (pro-B,
pre-B and naive-B) and spleen (transitional, marginal zone and
follicular), with greatest expression of HDAC9TG found in the
splenic marginal zone (Fig. 2B,C). When analyzed between 6 and
12 months of age, a fraction (3/17, 18%) of Eµ-HDAC9 mice
exhibited splenomegaly (Fig. S3A,B), compared to 0/10 wild-type
littermates. Histopathology and fluorescence-activated cell sorting
(FACS) analysis revealed evidence of abnormal B-cell expansion in
the spleen, compatible with the development of lymphoproliferative
disorder (LPD) (n=1), and splenic MZL (SMZL) (n=2); no
abnormalities were observed in control mice (0/10) (P<0.0001)
(Fig. S3A-C). Analysis of immunoglobulin (Ig) gene
rearrangements in these mice confirmed monoclonal expansions
of B-cell populations in 2/3 young-adult Eµ-HDAC9 mice at
8 months of age (Table 1). These results closely mirror those for a
GEM model constitutively expressing BCL6 in B cells under the
control of the immunoglobulin heavy chain (IgH) Iµ promoter
(Cattoretti et al., 2005). A remarkably similar fraction of these mice
(4/24, 17%) also displayed LPD at 6 months of age, representing
early stages of lymphomagenesis before the evolution and onset of a
B-cell neoplasm later in life (Cattoretti et al., 2005).
With age (i.e. past 14 months), Eµ-HDAC9 mice developed a
significantly higher frequency of lymphoproliferations compared to
control animals, such that, by 21 months of age, 48% of Eµ-HDAC9
mice survived compared with 95% of wild-type control mice
(P=0.0010, Fig. 3A). Phenotypic analysis in a subset of animals
revealed that approximately 40% (line 1469), 50% (line 1468) and
20% (line 1839) of Eµ-HDAC9 mice developed B-cell lymphomas,
compared to a minor fraction (5%) of wild-type littermates that
exhibited evidence of B cell malignancies (P<0.0001) (Fig. 3B).
Flow cytometric analysis of tumors from spleens of adult
Eµ-HDAC9 mice displayed a mature B-cell immunophenotypic
profile (B220dull, IgDlow/neg, IgMhigh, CD23neg and CD21neg)
(Fig. S4). Eµ-HDAC9 B-cell tumors were primarily of splenic
origin (Fig. 3C,D), with or without nodal involvement, expressed
B220, indicating B-cell derivation, and were histologically defined
as LPD, SMZL and DLBCL (Table 1). An additional 20% of
Eµ-HDAC9 mice either developed splenic B-cell lymphoma/
leukemia (SBCL/L) or another hematological malignancy, such as
histiocytic sarcoma (Table 1).
Molecular analysis of the rearranged IgH genes from Eµ-HDAC9
B-NHL samples confirmed their monoclonal origin (Fig. 3E) with
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evidence of somatic hypermutation (SHM) of IgV genes in 4/7
(57%) of tumors (Fig. S5). Thus, we concluded that Eµ-HDAC9
lymphomas and LPDs were derived from B-cell precursors, with
evidence of transit through the GC or having experienced the GC
reaction. In mice, the lymphomas and LPDs exhibited both GC and
post-/non-GC immunophenotypes (Table 1). Immunohistochemical
analysis revealed heterogeneous expression of BCL6, including
cases that were below the detection level by immunohistochemistry
(IHC), as previously observed in Iμ-BCL6-derived lymphomas
(Cattoretti et al., 2005). Eµ-HDAC9 tumors were also found to
express variable levels of IRF4 (MUM1), a marker for GC B cells
and plasma cells, and typically found in non-GC-type DLBCL
(Fig. 4 and Table 1) (Falini et al., 2000).
We next performed gene expression analysis, and a comparison
of three representative DLBCLs from Eμ-HDAC9 mice versus
normal B-cell populations indicated that Eµ-HDAC9 B-cell tumors
cluster with GC B cells and separately from non-GC B cells, further
supporting a GC origin, comparable with human tumors (Fig. 5A).
We also compared the expression pattern of DLBCLs from
Eμ-HDAC9 mice with three age- and gender-matched wild-type
controls, identifying a total of 1469 upregulated and 307
downregulated transcripts (Table S2). Among the upregulated
genes, pathway analysis using KEGG and gene ontology (GO)
annotated databases revealed enrichment for genes involved in the
cell cycle, cell division and response to DNA damage (Fig. 5B,
Table 2, and Tables S3 and S4). Pathway-based hierarchical
clustering (Good, 2000) for genes differentially expressed in
Eμ-HDAC9 mice (Tables S5, S6 and S7) confirmed regulation of
cell-cycle-related genes and pointed to modulation of MAPK/ERK
pathways. Furthermore, analysis of predicted protein–protein
interactions between KEGG-classified genes from HDAC9TG B-
cell tumors (Table S2) showed high network connectivity (Fig. 5C).
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Fig. 1. HDAC9 is highlyexpressed in humanB-cell lymphomas. (A) HDAC9expression in germinal center (GC) lymphatic nodules of normal human tonsils. Left
panels, immunohistochemical staining for HDAC9 (red). Cells were nuclear counterstained with hematoxylin (blue). Right panels, immunofluorescent analysis of
HDAC9 (red) and BCL6 (green) co-expression. SE, subepithelial cells; MZ, marginal zone. (B) Expression of HDAC family members in purified mature B-cell
subpopulations (naive, GC, memory). Expression patterns of BCL6, AICDA and BCL2 are shown as controls. Individual columns correspond to independent
samples. The color scale reflects the range in expression values after log2 transformation (0, mean expression level; red, high expression; blue, low expression).
Expression data from Klein et al. (2003). (C) Average signal intensity of HDAC9 staining in the indicated samples was scored as negative (0; gray), low (1; blue) or
high (2; red) relative to rectal adenocarcinomacells expressingHDAC9. Samples containing cells expressing on averageHDAC9with equal or higher intensitywere
scored as 2 and samples with lower expression were scored as 1. Cells lacking expression of HDAC9 were scored as 0. (D) Representative images of HDAC9
expression. Expression of HDAC9 in rectal adenocarcinoma is shown as a positive control. DLBCL, diffuse large B-cell lymphoma; GC, germinal cell; ABC,
activatedB-cell; CHL, classical Hodgkin lymphoma; FL, follicular lymphoma;MCL,mantle cell lymphoma;MZL,marginal zone lymphoma; LN, reactive lymphnode.
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A number of differentially expressed genes from the Eμ-HDAC9-
driven B-cell tumors were identified as direct targets for BCL6 and
p53 that have roles in apoptosis, the cell cycle and B-cell receptor
(BCR) signaling (Table S2). Additionally, signal transduction
pathways revealed substantial enrichment for genes involved in
G1/S and G2/M transition followed by the Polo-like kinase 1
(PLK1) pathway (Fig. 5D). Among the most upregulated genes
found in HDAC9TG B-cell tumors were those encoding factors such
as Plk1, Birc5, Cdk1, Aurka, Aurkb and Chek1, which are involved
in proliferation and survival, G1/S and G2/M transitions, mitosis
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Fig. 2. Characterization of Eµ-HDAC9 transgenic
mice. (A) Western blot analysis for detection of
HDAC9TG expression with monoclonal anti-FLAG M2
antibody. HeLa cells, which lack expression of FLAG,
and HeLa cells transfected with FLAG-tagged HDAC9
are shown as negative and positive controls,
respectively. (B)HDAC9TG (TG) transcript expression in
B-cell subsets. mRNA transcripts for HDAC9 were
analyzed by quantitative reverse transcription PCR
(RT-qPCR) from HDAC9TG (TG, red) spleen (left) or
bone marrow (right) versus controls from wild-type
littermates (WT, blue). RNA from three individuals
(spleen) or five individuals (bone marrow) was pooled
and values are expressed as the fold change in
transcript abundance (±s.d.) compared with values for
WTmice. Transitional B-cell (B-Tr), P<0.0001; marginal
zone B-cell (B-MZ), P<0.0001; follicular B-cell (B-Fo),
P<0.0001; Pro B-cell (Pro-B), P=0.0010; Pre B-cell
(Pre-B), P<0.0001; IgM-positive/mature B-cell
(IgMpos-B), P<0.0001. (C) Immunohistochemical
analysis of HDAC9TG expression in spleen from two
Eµ-HDAC9 mice and a wild-type littermate control.
HDAC9 expression was detected with anti-FLAG
M2 antibody and stained red with AEC
(3-amino-9-ethylcarbazole). Cells were nuclear
counterstained with hematoxylin. In Eµ-HDAC9 spleen,
expression of HDAC9TG is highest in the marginal
zone and white pulp (B-cell zone). MZ, marginal zone;
CA, central arteriole; PALS, periarteriolar lymphoid
sheath (T-cell zone); GC, germinal center; B, primary
follicles B-cell rich (B-cell zone).
Table 1. Tumor type and IgH rearrangements in Eμ-HDAC9 mice
Immunohistochemistry
Mouse Histopathology Clonal statusa IgHVb JH B220 CD3 BCL6 IRF4 GC
1452c SMZL Mono ND JH3 ND ND ND ND U
1714 SMZL Mono, UM − JH2 + − − − −
1839 SMZL Mono, UM − JH3 + − − +/− −
1851 DLBCL Mono, M(21) IgHV5 JH4 + − + +/− +
1759 DLBCL Mono ND ND + − + +/− +
1454c SMZL Oligo, M(28) IgHV1,2,5 JH4 ND ND ND ND +
1469 LPD Mono ND JH3 ND ND ND ND U
1546 SBCL/L, NOS Mono IgHV1 JH2 ND ND ND ND U
1543 SBCL/L, NOS Mono ND JH4 ND ND ND ND U
1578 HS ND ND ND ND ND ND ND U
4259 HS ND ND ND − − − − U
4698c LPD ND ND ND ND ND ND ND −
Classification based on H&E analysis. Italics: histopathology diagnosis only.
SMZL, splenic marginal zone lymphoma; DLBCL, diffuse large B-cell lymphoma; LPD, lymphoproliferative disease; SBCL/L, NOS, small B-cell lymphoma/
leukemia not otherwise specified; HS, histiocytic sarcoma; U, unknown; Mono, monoclonal; Oligo, oligoclonal; ND, not determined; M(n), mutated (number of
mutations); UM, unmutated; GC, germinal center phenotype; +, expression of protein; –, no expression of protein; +/−, variable expression of protein.
aPCR products from tumors were compared to wild-type B cells to detect allele rearrangements.
bMouse IMGT IgHV subgroup.
cAnalyzed at 8 months of age.
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and DNA-repair/checkpoint-mediated arrest (Table 2). A role for
HDAC9 in proliferation and control of the cell cycle was confirmed
by zinc-finger nuclease (ZFN)-mediated gene editing of HDAC9
(Fig. 6). Monoallelic knockout of HDAC9 in the Raji Burkitt’s
lymphoma cell line (biallelic forms were non-viable; data not
shown) led to reductions in HDAC9, consistent with a decrease in
gene dosage (Fig. 6A). This resulted in growth inhibition (Fig. 6B,
C) and an increase in the proportion of cells in S and G2/M phases
(Fig. 6D).
A potential role for HDAC9 in the pathogenesis of B-NHL is
strengthened by its interaction with BCL6 (Petrie et al., 2003), a
transcriptional repressor crucial for GC formation (Basso and Dalla-
Favera, 2012) and whose deregulated expression in B cells leads to
LPD and B-NHL (Cattoretti et al., 2005). BCL6 directly recruits
class-II HDACs through its zinc-finger domain (Lemercier et al.,
2002) and its transcriptional targets in GC B cells include TP53,
thus modulating DNA-damage-induced apoptotic responses (Phan
and Dalla-Favera, 2004). BCL6 and p53 function in a negative-
feedback loop whereby p53 promotes BCL6 expression, which in
turn suppresses the expression of TP53 (Margalit et al., 2006; Phan
and Dalla-Favera, 2004). The BCL6–p53 axis is further modulated
by post-translational acetylation of BCL6, which leads to its
inactivation. Indicative of a potential role for HDAC9 in the
acetylation of BCL6 in vivo, acetylated BCL6 was found to be
abundant in normal mouse spleens but undetectable in HDAC9TG
tumors (Fig. 7A). p53 is also post-translationally modified by
acetylation, which is indispensable for its transcriptional activity in
response to DNA damage and stress (Tang et al., 2008).
Highlighting the loss of p53 tumor suppressor function as a
contributory factor in the development of B-cell lymphomas,
B-cell-specific disruption of TP53 leads to the development of
B-NHL (Chiang et al., 2012). Consistent with this, as well as with
recent research demonstrating that HDAC9 binds to the TP53
promoter to repress gene expression (Zhao et al., 2015), we found
diminished levels of total p53 as well as Lys379 acetyl-p53 in
Eµ-HDAC9 tumors (Fig. 7B,C).
DISCUSSION
HDAC9 is highly expressed in B-NHL cell lines and patient samples
(Petrie et al., 2003; Sun et al., 2011), and its locus, chromosome
7p21.1, is frequently amplified in B-NHL (Bea et al., 2005; Bentz
et al., 1999; Monni et al., 1996; Rubio-Moscardo et al., 2005;
Tagawa et al., 2005). In order to establish whether deregulated
expression of HDAC9 in the lymphoid compartment could generate
a disease phenotype, we designed a GEM model in which a human
HDAC9 transgene was expressed under the control of the Eµ
promoter. Our hypothesis was based on evidence of deregulation of
HDAC9 expression in B-NHL cell lines and patient samples. The
occurrence of B-NHL in these transgenic mice strongly indicates a
link between deregulated HDAC9 expression and lymphoid
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Fig. 3. Frequency of lymphoproliferative disease (LPD) and B-cell lymphoma (B-NHL) in Eµ-HDAC9mice. (A) Incidence of B-NHL (red) and LPD (blue) in
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(D) Representative Eµ-HDAC9 spleen infiltrated by DLBCL (top) compared towild-type littermate control spleen (bottom). (E) Analysis of rearranged IgH genes in
Eµ-HDAC9 splenic marginal zone lymphoma (SMZL). Shown is a monoclonal D-JH rearrangement confirmed by sequencing (D-JH2, 1.1 kb). Also shown is
polyclonal rearrangement of a wild-type littermate control. Tail DNA was used for germline configuration.
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neoplasia, the first time that overexpression of a histone deacetylase
in mice has resulted in a cancer phenotype. This is also, to our
knowledge, the first time that expression of a single epigenetic
transgene has led to lymphoma – expression of mutated polycomb-
group gene EZH2 fails to drive lymphomagenesis unless in a
background of overexpressed BCL2 or Myc (Béguelin et al., 2013;
Berg et al., 2014). This does not, however, rule out a requirement for
the acquisition of additional mutations in order for progression to
lymphoma in Eµ-HDAC9 mice. Our results are also in agreement
with a recent study utilizing an MRL/lpr GEM model of systemic
lupus erythematosus with HDAC9 deficiency (Yan et al., 2011).
Here,MRL/lpr transgenic mice lackingHDAC9 displayed decreased
lymphoproliferation and expression of BCL6. Although the SMZL
cases studied in Eµ-HDAC9 mice were BCL6-negative, it is
generally accepted that MZL in humans is derived from a post-
GC B cell, with associated somatic mutations in the IgVH gene
(Dunn-Walters et al., 1998; Miranda et al., 1999; Zhu et al., 1995).
Moreover, progression of indolent lymphoma (SMZL) to a more
aggressive lymphoma (DLBCL) is a frequent occurrence for many
subtypes of indolent B-cell lymphomas and could explain the late
onset of aggressive lymphomas observed in our transgenic model
(Camacho et al., 2001; Freedman, 2005). The development of
SMZL in Eµ-HDAC9mice is also consistent with results obtained in
mice in which TP53was disrupted specifically in B cells, leading to
the development of highly penetrant SMZL (Chiang et al., 2012).
Our results indicated that aberrant expression of HDAC9 in B
cells leads to the upregulation of pathways that promote cell growth
and survival, as well as impacting the activity and expression of key
factors in lymphoma BCL6 and p53. The notion that transgenic
expression of HDAC9 can promote lymphomagenesis, in part
through deregulation of the activities of p53, is strengthened by
studies suggesting that p53 might directly bind to the HDAC9
promoter and repress its expression (Akdemir et al., 2014;Wei et al.,
2006). Of note, the p53-binding site in the HDAC9 promoter
overlaps with a myocyte enhancer factor 2 (MEF2)-binding site,
which, when bound by MEF2 family members, activates HDAC9
gene expression (Haberland et al., 2007). Activating mutations of
MEF2B (which occur in 11% of DLBCL and 12% of FL) have been
reported to directly upregulate expression of BCL6 (the promoter of
which also contains a MEF2-binding site) in GC B cells and drives
DLBCL proliferation (Ying et al., 2013). It remains to be established
whether mutant MEF2B can drive HDAC9 expression in B-cell
lymphomas, but recent research has identified a novel MEF2D–
BCL9 fusion protein associated with high-risk acute B-cell
precursor lymphoblastic leukemia (ALL) that directly upregulates
HDAC9 (Suzuki et al., 2016). High expression of HDAC9 has been
independently linked to poor prognosis in ALL (Moreno et al.,
2010).
In recent years, numerous structurally diverse HDAC inhibitors
(HDACi) have emerged as clinical candidate therapeutic agents (West
and Johnstone, 2014), including the recent development of class-IIa-
specific HDACi (Lobera et al., 2013). Even in the case of cutaneous
T-cell lymphoma (CTCL) where HDACi have shown efficacy as
single-agent targeted therapies and been approved for use in the clinic
(Prince and Dickinson, 2012), the use of HDACi in rational
combinations will likely maximize their therapeutic potential. It is,
Wild type SMZL DLBCL
Eµ-HDAC9
A B C
D E F
G H I J K
50 µm
50 µm 50 µm 50 µm 50 µm
50 µm 20 µm 20 µm50 µm
50 µm50 µm50 µm 50 µm 50 µm
Fig. 4. Histopathological analysis of mature B-cell lymphomas in Eµ-HDAC9mice. Representative images showing disorganization of lymphoid tissue and
expression of B220, CD3 and BCL6. Mouse spleen sections fromwild type, splenic marginal zone lymphoma (SMZL) and diffuse large B-cell lymphoma (DLBCL)
cases (as indicated) were stained with hematoxylin-eosin (A-C), doubled stained with B220 (blue)/CD3 (brown) (D-F), or BCL6 (blue) (G-J). IRF4 expression is
shown in panels I and K.
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therefore, of interest that genes upregulated in Eµ-HDAC9 tumors,
such as Cdk1, Chek1, Aurka and Aurkb, represent important clinical
targets for which late-phase clinical trials are ongoing (Garrett and
Collins, 2011; Lapenna and Giordano, 2009; Micel et al., 2013). The
upregulation of Plk1 is also of potential clinical interest given that its
high expression is a negative prognostic indicator in B-NHL (Liu et
al,. 2007; Xu et al., 2013; Yim et al., 2013). PLK1 plays a crucial role
at checkpoint controls duringG2/M transition of the mitotic cell cycle
(Barr et al., 2004) and inhibits p53 function directly by
phosphorylation (Ando et al., 2004). Therefore, the Eµ-HDAC9
GEM model could serve as a valuable tool both to better understand
the molecular mechanisms involved in lymphomagenesis in humans
and facilitate preclinical studies of new drugs and combination
therapies.
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Fig. 5. Expression microarray
analysis of Eµ-HDAC9 tumors.
(A) Unsupervised hierarchical
clustering of gene expression data
from representative Eµ-HDAC9-
derived (TG) lymphomas (n=3) versus
normal murine mature B-cell
subpopulations, including germinal
center (GC), follicular (FO) and
marginal zone (MZ) B cells
(GSE15907). Color scale represents
the range in relative expression
changes (Z score) across samples,
normalized by the standard deviation
after log2 transformation (0, mean
expression level; red, high expression;
blue, low expression). (B) Functional
annotation of upregulated gene
expression in HDAC9TG tumors
according to biological process.
Values represent the number of
upregulated genes for a given gene
ontology (GO) term. A complete list of
annotated genes for identified GO
functional categories is shown in
Table S5. Gene annotation was
performed using Partek Genomics
Suite 6.6. (C) Interactome of
upregulated genes in HDAC9TG B-cell
tumors. Interactions were analyzed
using STRING v9.1. Thicker lines
define stronger associations in the
interactome. (D) Functional annotation
of expression of signal transduction
pathway genes upregulated in
HDAC9TG tumors. Gene sets from
HDAC9TG B-cell tumors were
analyzed using GGA (Genomatix
Genome Analyzer) and ranked
according to P-value.
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MATERIALS AND METHODS
Generation of Eμ-HDAC9 transgenic mice
FLAG-epitope-tagged full-length human HDAC9 cDNAwas cloned into the
pEμSR vector, placing the HDAC9-sequence-containing oligonucleotide
cassette downstream of the immunoglobulin heavy chain (IgH) enhancer (Eμ)
and the SRα potent promoter (Bodrug et al., 1994). The Eμ-HDAC9
transgenic fragmentwas isolated from the vector by enzymatic digestion using
the NotI restriction sites and injected into B6CBAF1 pronuclei. Mice were
backcrossed and maintained in a C57BL/6 background to generate three
transgenic lines: 1468, 1469 and 1839. PCR genotyping was performed
using SV40 primers: F: 5′-GGAACTGATGAATGGGAGCA-3′ and R:
5′-GCAGTGCAGCTTTTTCCTTT-3′. Mice were housed and maintained in
accordance with UK Home Office regulations. Animals were monitored and
analyzed from birth to 23 months of age and sacrificed if showing signs of
illness. Statistical analysis was performed using Prism (GraphPad Software).
Kaplan–Meier cumulative survival and the log-rank (Mantel–Cox) test were
used to determine tumor-free survival and the χ2 test was used to compare
B-NHL incidence in Eµ-HDAC9mice versus wild-type controls. P<0.05 was
considered statistically significant. All experimental protocols weremonitored
and approved by The Institute of Cancer Research Animal Welfare and
Ethical Review Body, in compliance with guidelines specified by the UK
Home Office Animals (Scientific Procedures) Act 1986 and the United
Kingdom National Cancer Research Institute guidelines for the welfare of
animals in cancer research (Workman et al., 2010). ARRIVE guidelines were
applied when reporting in vivo experiments (Kilkenny et al., 2010).
Ig gene rearrangements analysis
Genomic DNA was isolated from tumor specimens and prepared using All
Prep Kit (Qiagen). Primers for detection of Ig rearrangements were
described previously (Ehlich et al., 1994). D-JH rearrangements of the heavy
chain (JH) locus were amplified and detected in a multiplex PCR reaction
using two upstream primers, DFL/DSP and DQ52, together with one
reverse primer positioned downstream of JH4 (Mårtensson et al., 1997). For
mutational analysis, the rearranged Ig variable heavy chain genes were
amplified from genomic DNA as previously described (Cattoretti et al.,
2005). V-DJH rearrangements were analyzed in separate PCR reactions
using primers VHJ558a (5′-CAGGTCCAGCTGCAGCAGTCTGG-3′),
VH7183b (5′-GTGAAGCCTGGAGGGTCCC-3′), VHQ52 (5′-CAGGTG-
CAGCTGAAACAGTCA-3′) and reverse JH4 primer (5′-TGAGGAGA-
CGGTGACTGAGGTTCC-3′). The primers amplified all rearrangement
products between JH4 and VHJ558, VH7183 or VHQ52 where four different
bands would be expected by the combination of each primer set. PCR
cycling conditions were: 95°C for 5 min, 95°C for 30 s, 63°C for 30 s and
72°C for 2 min, for 35 cycles. PCR products were gel-purified using the
QIAQuick method (Qiagen) and directly sequenced using the ABI PRISM
3130xl Genetic Analyzer (Applied Biosystems). Sequences were aligned to
those in the international ImMunoGeneTics information system (IMGT)
database.
Flow cytometry and cell sorting
Single-cell suspensions were obtained from dissected tissues, washed in
phosphate buffered saline (PBS) supplemented with 0.2% FBS, filtered
through a 45 µm cell strainer and red blood cells were lysed using
ammonium chloride solution (STEMCELL Technologies). The antibody
combination used for tumor analysis included: CD23, CD19, IgM, IgD,
CD21 and B220. Anti-mouse conjugated antibodies were obtained from
eBioscience and BioLegend. Cell sorting of splenic CD19-positive mouse B
cells was carried out using immunomagnetic isolation with CD19-labeled
beads (EasySep Mouse CD19 Positive Selection Kit, STEMCELL
Technologies) and purity assessed using anti-mouse PE-conjugated CD19
antibody (eBioscience). Data were acquired on a FACS LSRII analyzer (BD
Biosciences) and analyzed using FlowJo software (Tree Star).
Transgenic transcript detection
Total RNA frommouse bonemarrow and spleen was extracted using TRIzol
reagent (15596-026, Ambion) following the manufacturer’s instructions.
Reverse transcription was performed following standard protocol by using
AccessQuick Master Mix (A1701, Promega). Real-time quantitative PCR
was carried out using Fast SYBR Green Master Mix (4385612, Applied
Biosystems). Primer sets used to detect mouse and human HDAC9
transcripts in B-cell subsets: F: 5′-TCTGGATGTTCACCATGGAA-3′
and R: 5′-CACTGCCAGGGAAAAAGTTC-3′. Primer sets to detect mouse
Hdac9: F: 5′-GGTGATGATTCTCGGAAATTCT-3′ and R: 5′-GAAGC-
CAGCTCAATGACACA-3′. Abl1 mRNA expression was used as normal-
ization control, F: 5′-CAGCGGCCAGTAGCATCTGACTT-3′ and R:
5′-GCTTCACACCATTCCCCATT-3′.
Table 2. Gene expression profiling of Eμ-HDAC9 tumors
Gene Fold change Accession #
Mki67 3.9 NM_001081117
Asns 3.4 NM_012055
Ccna2 3.1 NM_009828
Cdc6 3.1 NM_011799
Ube2c 3 NM_026785
Plk1 2.6 NM_011121
Top2a 2.6 NM_011623
Kif11 2.6 NM_010615
H2afx 2.6 NM_010436
Prc1 2.5 NM_145150
Ccnb2 2.4 NM_007630
E2f8 2.4 NM_001013368
Cdk1 2.3 NM_007659
Sgol1 2.3 NM_028232
Il1b 2.3 NM_008361
Kif18b 2.3 AK013867
Birc5 2.2 NM_009689
Cdkn3 2.2 NM_028222
Anln 2.2 NM_028390
Aspm 2.2 NM_009791
Ezh2 2.1 NM_007971
Dlgap5 2.1 NM_144553
Mcm10 2.1 NM_027290
Bub1b 2.1 NM_009773
Ect2 2.1 NM_007900
Chek1 2.1 ENSMUST00000173796
Nusap1 2.1 NM_001042652
Tpx2 2.1 NM_028109
Ncapg2 2.1 NM_133762
Slfn1 2.1 NM_011407
Cenpf 2.1 AK029517
Casc5 2.1 NM_029617
Sept 2.1 AK144178
Gpsm2 2.1 Trans_XM_002726048
Esco2 2.1 NM_028039
Ncapg 2.1 NM_019438
Ptgs2 2.1 NM_011198
F630043A04Rik 2 AK_158142
Cks1b 2 NM_016904
Cdca3 2 NM_013538
Bcl2l1 2 NM_009743
Aurkb 2 NM_011496
Cd28 2 NM_007642
Aurka 2 ENSMUST00000128004
Sgol2 2 AK079371
Dtl 2 NM_029766
Ccne2 2 NM_009830
Cdca2 2 ENSMUST00000124045
Bub1 2 NM_009772
Cit 2 AK048090
Nuf2 2 NM_023284
Bcat1 2 ENSMUST00000145911
Cdc20 2 AK029424
Kif2c 2 AK015046
Fignl1 2 NM_001163360
Steap3 2 NM_133186
Trp53inp1 2 AK054214
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Purification of B-cell subsets
Single-cell suspensions from spleen (n=3) and bone marrow (n=5) from 8-
to 12-week-old mice (transgenic and wild type) were prepared as previously
described (Green et al., 2011). Bone marrow and spleen B-cell
subpopulations were identified and sorted by three-color FACS method
(Green et al., 2011). Anti-mouse antibodies CD43, IgM and B220were used
to obtain Pro-B, Pre-B and Mature-B-cell fractions from bone marrow.
Splenic B-cell subtypes, follicular and marginal zone, were purified using
anti-mouse CD19, CD21 and CD23 antibodies, whereas a combination of
anti-mouse B220, IgM and CD93 was used to sort for transitional B cells.
Each subset was above 90% purity. Purified cells were re-suspended in
TRIzol reagent (Life Technologies) for further RNA extraction.
Histopathology and immunohistochemistry (IHC)
Tissues were freshly collected and fixed in 10% formalin for 24 h, embedded
in paraffin and sectioned. Following deparaffinization and rehydration,
samples were pre-treated with antigen-unmasking solution (Vector
Laboratories, H-3300). After pre-treatment, tissue sections were blocked in
Tris-NaCl buffer, washed in PBS and permeabilized in 0.5% Triton X-100.
Slides were washed in Tris-NaCl-Tween buffer and reacted with primary
antibody overnight at 4°C. Preliminary experiments were performed to
determine optimal dilutions for each primary antibody used. Detection
methods included: standard IHC, Vectastain Elite ABC system, Vector
Laboratories or EnVision system (Dako) DAB staining and ABC-tyramide
signal amplification (TSA Plus Fluorescence System, Perkin Elmer) (see
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below). Histopathological evaluation of HDAC9TG tumors was performed
using hematoxylin and eosin (H&E)-stained sections. Immunophenotypic
characterization of theHDAC9TG lymphomaswas performed using antibodies
against B220, PAX5, CD3, BCL6 and IRF4 as previously described
(Mandelbaum et al., 2010). Human HDAC9 expression was assessed by
IHC using tissue microarrays and/or individual tumor sections of 59 B-NHLs
and three CHLs using a specific antibody generated against the C-terminal
region of HDAC9 (Petrie et al., 2003). The B-NHL group consisted of 34
DLBCLs, nine FLs, five MZLs, six MCLs and two chronic lymphocytic
leukemias/small lymphocytic lymphomas (CLLs/SLLs). Nuclear expression
intensity of lymphomas was compared with that of rectal adenocarcinoma
cells (positive control). If equal or higher intensity than control, HDAC9
expression was considered high (score 2+), and, if low, scored 1+.
Immunoblotting and antibody validation
Cell lysates were prepared using RIPA buffer supplemented with protease
inhibitors (Roche). Rat monoclonal (IgM) antibody specific to the
C-terminus of human HDAC9 (clone 45a7b5b) was developed using a
synthetic peptide (DVEQPFAQEDSRTAG) conjugated to Diphtheria
toxoid (Mimotopes), corresponding to unique amino acids 1046-1060.
Validation was performed using Mini-PROTEAN II Multiscreen Apparatus
(Bio-Rad). Other antibodies used for immunoblots included mouse
monoclonal anti-FLAG M2 antibody (F1804, Sigma), β-actin loading-
control antibody (BA3R) (MA5-15739, Thermo Scientific) and acetyl-p53
(Lys379) (PA5-17287, Thermo Scientific).
IHC and immunofluorescence detection methods
Single immunolabeling using ABC-TSA
Formalin-fixed paraffin-embedded tissue sections were dried for 45 min at
58°C, followed by deparaffinization and hydration in Histoclear (National
Diagnostics) and a graded series of ethanol, respectively. Samples were
pretreated by microwave incubation in a pH 6.0 citrate-based antigen-
unmasking solution (Vector Laboratories, H-3300) followed by 2×5 min
washes in PBS and permeabilization in 0.5% Triton X-100 (in PBS) for
20 min at room temperature (RT). Samples were washed in PBS prior to
blocking for 30 min at RT in Tris-NaCl (TNB) blocking buffer with
subsequent incubation in the monoclonal anti-HDAC9 antibody (clone
45a7b5b, 1/100 dilution) overnight at 4°C. Primary antibody was followed
by biotinylated rabbit anti-rat secondary antibody for 30 min at RT.
Endogenous peroxidase activity was inactivated by incubation with 3%
hydrogen peroxide in methanol for 15 min at RT. After washing in Tris–
NaCl–Tween-20 (TNT) buffer, samples were incubated in streptavidin
(SA)-horseradish peroxidase (HRP) (Vectastain ABC Elite Kit, Vector
Laboratories, PK-6104) for 45 min at RT. Following this, FITC fluorophore
tyramide (Perkin Elmer, NEL741) was added for 10 min at RT, which
results in the deposition of numerous fluorophore labels adjacent to the
HRP. This fluorescent signal was then converted to a chromogenic signal by
the addition of HRP-labeled anti-FITC (Perkin Elmer, NEF710), 1/200
dilution in TNB for 45 min at RT, 3×5 min washes in TNT and incubation in
chromogen 3-amino-9-ethylcarbazole (AEC) (BUF019B, AbD Serotec).
Hematoxylin QS (Vector Laboratories, H-3404) was utilized for nuclear
counterstaining and the sections mounted in Vectamount aqueous mounting
medium (Vector Laboratories, H-5501). Images were collected on a Zeiss
Axioskop 2 light microscope utilizing Axiovision 4.4 software.
Double/triple labeling with ABC-TSA
The following immunolabeling reactions were applied using ABC-TSA
method as described elsewhere (Asson-Batres and Smith, 2006).
Preliminary controls showed no antibody carryover when one primary
antibody was a rabbit polyclonal and the other was a rat monoclonal
antibody, or when both primary antibodies were made in rabbits. Images
were collected on Zeiss LSM700 confocal microscope using Zen 2009
software with sequential collection to prevent any spectral crosstalk.
Double immunolabeling
Formalin-fixed paraffin-embedded tissue sections were dried for 45 min at
58°C followed by deparaffinization and hydration in Histoclear (National
Diagnostics) and a graded series of ethanol, respectively. Samples were
pre-treated by microwave incubation in a pH 6.0 citrate-based antigen-
unmasking solution (Vector Laboratories, H-3300) followed by 2×5 min
washes in PBS and permeabilization in 0.5% Triton X-100 in PBS for
20 min at RT. Samples were then washed in PBS prior to blocking for
30 min at RT in TNB blocking buffer with subsequent incubation in the
monoclonal anti-HDAC9 antibody (clone 45a7b5b, 1/100 dilution)
overnight at 4°C. Primary antibody was followed by biotinylated rabbit
anti-rat secondary antibody (Vectastain ABC Elite Kit, Vector Laboratories,
PK-6104) for 30 min at RT. Endogenous peroxidase activity was quenched
by incubation in 3% hydrogen peroxide (in methanol) for 15 min at RT.
After washing in TNT buffer, samples were incubated in SA-HRP
(Vectastain, Vector Laboratories ABC Elite Kit, PK-6104) for 45 min at
RT. Next, a Cy3 fluorophore tyramide (Perkin Elmer, NEL741) was added
(1/50 dilution prepared in the supplied amplification buffer) for 10 min at
RT, which results in the deposition of numerous fluorophore labels adjacent
to the HRP. Slides werewashed 3×5 min in TNT buffer, any remaining HRP
was deactivated by incubating in 3% hydrogen peroxide (in methanol) for
15 min at RT. A second primary antibody was added sequentially [anti-
acetylated p53 (Lys379) Thermo Scientific, cat. # 17287, 1/100 dilution]
and the protocol was repeated with the FITC fluorophore tyramide (Perkin
Elmer, NEL741) utilized to detect acetylated p53. Slides were
counterstained with To-pro 3 iodide (Life Technologies, T-3605) and
mounted in Vectashield (Vector Laboratories, cat. # H-1000) mounting
medium. Negative control slides were prepared by excluding the primary
antibody, by excluding the conjugated secondary antibody-fluorophore and
by excluding TSA reagents; negative controls showed no immunoreactivity.
Single-labeling experiments carried out to observe the patterns of staining of
each primary antibody validated the double-immunostaining results.
Triple immunolabeling
First, the primary antibodies monoclonal rat anti-HDAC9 (clone 7b5b,
1/100 dilution) and rabbit polyclonal anti-acetylated lysine (Millipore 06-
933, 1/500 dilution) were added together and left overnight at 4°C.
Following this, secondary anti-rat biotinylated antibody (1/200 dilution)
was added and the TSA protocol was carried out using Cy3 fluorophore
tyramide (Perkin Elmer, NEL753). Next, HRP was inactivated before the
secondary antibody against acetylated lysine was added (anti-rabbit
biotinylated) and the TSA protocol followed using FITC fluorophore
tyramide (Perkin Elmer, NEL753). The HRP was once again inactivated
with 3% hydrogen peroxide (in methanol) for 15 min at RT and rabbit
polyclonal anti-BCL6 antibody (ab19011) (1/1000 dilution) was added
(overnight at 4°C). Following this, the TSA protocol was applied using Cy5
fluorophore tyramide (Perkin Elmer, NEL745). Secondary-antibody
controls were performed to detect any non-specific background staining.
Single-staining controls were carried out as in the same-species double-
labeling experiments.
IHC of human tumors
The EnVision detection system HRP/DAB+ (Dako) was used as previously
described (Kim et al., 2009). Briefly, tissue sections were deparaffinized in
xylene and rehydrated in ethanol following treatment in pre-heated target
retrieval solution. Following washes, serum-free blocking solution was
applied for 40 min at RT. In-house anti-HDAC9 monoclonal antibody was
used overnight at 4°C then treated with polymer/HRP and DAB. After
washes, the slides were counterstained with hematoxylin, dried and
mounted with Permount. Photomicrographs were captured using an
Olympus BX41 dual head light microscope equipped with an Olympus
Q-Color 5 digital camera (Olympus America).
Antibodies IHC/IF
Primary antibodies included polyclonal rabbit anti-Ac-p53 (Lys379)
(Thermo Scientific), monoclonal rat anti-HDAC9 antibody (clone
45a7b5b), monoclonal mouse anti-FLAG M2 (Sigma), polyclonal rabbit
anti-acetylated lysine (Millipore 06-933), polyclonal rabbit anti-BCL6
(ab19011), anti-CD45R(B220) (ab64100) and anti-CD3 (ab5690).
Secondary antibodies included: biotinylated rabbit anti-rat secondary
antibody (Vector Laboratories, PK-6104), biotinylated horse anti-mouse
secondary (Vector Laboratories, PK6102) and biotinylated goat anti-rabbit
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secondary (Vector Laboratories, PK6101). Fluorochromes and chromogens
included SA-HRP (Vector Laboratories, PK-6102), FITC fluorophore
tyramide (Perkin Elmer, NEL741, NEL753), FITC-HRP (Perkin Elmer,
NEF710), Cy3 fluorophore tyramide (Perkin Elmer, NEL741, NEL753),
Cy5 fluorophore tyramide (Perkin Elmer, NEL745) and AEC (AbD Serotec,
BUF019B).
High-density SNP array analysis
Genome-wide DNA profiles were obtained from high-molecular-weight
genomic DNA of DLBCL patients using the Affymetrix Genome-Wide
Human SNP Array 6.0 (Affymetrix) following the manufacturer’s
instructions. Image data analysis and quality control for the hybridized
samples were performed using the Affymetrix Genotyping Console 3.0.1
software, and only samples passing the Affymetrix recommended contrast
QC and SNP call rates threshold (in the Birdseed v2.0 algorithm) were
considered for analysis. Affymetrix CEL files and corresponding SNP
genotype call files generated by the Affymetrix Genotyping Console tool
were then analyzed using the dCHIP software. Model-based expression was
performed using the perfect-match/mismatch (PM/MM) model to
summarize signal intensities for each probe set. Probe intensity data for
each array were normalized using a diploid reference set of three normal
(non-tumor) DNA samples that had been processed and hybridized in the
same experiment as the tumor samples. The standard invariant-set
normalization approach in dCHIP was implemented by a karyotype-
guided normalization method as previously described (Mullighan et al.,
2007; Pounds et al., 2009). To identify regions of amplification and deletion,
the circular binary segmentation algorithmwas applied to the SNP array data
as described (Mullighan et al., 2007). The following criteria were used to
obtain candidate genomic regions (gains or loss): (1) mean log2 ratios of
≥0.2 or ≤−0.2; (2) ≥8 SNP markers within a segment. The results of the
CBS algorithm were then compared to those of dCHIP. To exclude calls of
genomic gains or loss arising from inherited genomic copy number variants
(CNVs), the dCHIPSNP algorithm was also applied to 130 normal DNAs
from an independent study as well as to 230 normal DNAs from the HapMap
project; alterations identified in the pool of reference samples were
excluded. In addition, CNVs were excluded if present in the Database of
Genomic Variants (http://projects.tcag.ca/cgi-bin/variation/gbrowse/hg18/).
Gene expression analysis
Affymetrix GeneChip Mouse Gene 1.0 ST hybridizations were performed
using biotin end-labeled cDNA prepared from CD19-positive B cells
isolated from tumors. Unsupervised hierarchical clustering was performed
on gene expression data from representative HDAC9TG-derived lymphomas
versus normal murine mature B-cell subpopulations, including GC and non-
GC (follicular and marginal zone) B cells (GeneChip Mouse Gene 1.0 ST
Arrays). Data from normal B-cell subsets were obtained from the
Immunological Genome Project (GSE15907) (www.immgen.org). Only
probes with minimal expression level equal to 10 and minimal standard
deviation of 1.5 (log2 transformed) were considered. The hierarchical
clustering algorithm is based on the average-linkage, Pearson correlation.
Gene data sets were also analyzed for interactions and pathways using:
GGA (Genomatix Genome Analyzer, https://mygga.genomatix.de), the
Search Tool for the Retrieval of Interacting Genes/Proteins STRING v9.1
(http://string-db.org) to develop interactomes or networks (Franceschini
et al., 2013) and the KEGG pathway database (Kanehisa et al., 2004). GO
(Ashburner et al., 2000) clustering was performed with csbl.go (Ovaska
et al., 2008). Partek Genomics Suite 6.6 was additionally used for data set
analysis and comparisons.
Zinc-finger nuclease (ZFN) knockout of HDAC9
ZFNs targeting human HDAC9 sequence were obtained from Sigma-
Aldrich (CompoZr Knockout Zinc Finger Nucleases, CKOZFND9935-
1KT). The ZFN binding-cutting site (in lowercase) was 5′-CTCTGGTC-
CCAGTTCACCaaacaATGGGCCAACTGGAAGTG-3′. Delivery of ZFN
was performed following the manufacturer’s protocol (Sigma-Aldrich). The
human Burkitt’s lymphoma cell line Raji (ATCC CCL-86) was used for the
study. Cells were maintained in RPMI medium 1640 (1×) (Gibco)
supplemented with 10% FBS (Sigma-Aldrich) and grown in a 5% CO2
incubator at 37°C. Cells were transfected by nucleofection (electroporation)
using Amaxa Cell Line Nucleofector Kit V (Lonza), and grown for 48 h
followed by single-cell sorting in a 96-well format using BD FACS Aria
(BD Biosciences). After 3-4 weeks, single-cell-derived clones were
screened and analyzed using CEL-I assay (SURVEYORmutation detection
assay) following the manufacturer’s instructions (Transgenomic). Genomic
DNAwas obtained by high-throughput HotSHOTDNA preparation method
in 96-well plates. ZFN mutant clones were confirmed by sequencing.
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Tao, R., de Zoeten, E. F., Özkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B.,
Turka, L. A., Olson, E. N., Greene, M. I. et al. (2007). Deacetylase inhibition
promotes the generation and function of regulatory T cells. Nat. Med. 13,
1299-1307.
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong,
H. C., Fu, Y. T., Weng, Z. et al. (2006). A global map of p53 transcription-factor
binding sites in the human genome. Cell 124, 207-219.
West, A. C. and Johnstone, R. W. (2014). New and emerging HDAC inhibitors for
cancer treatment. J. Clin. Invest. 124, 30-39.
Witt, O., Deubzer, H. E., Milde, T. andOehme, I. (2009). HDAC family: what are the
cancer relevant targets? Cancer Lett. 277, 8-21.
Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin,
D. J., Double, J. A., Everitt, J., Farningham, D. A. H., Glennie, M. J. et al.
(2010). Guidelines for the welfare and use of animals in cancer research.
Br. J. Cancer 102, 1555-1577.
Xu, J., Shen, C., Wang, T. and Quan, J. (2013). Structural basis for the inhibition of
Polo-like kinase 1. Nat. Struct. Mol. Biol. 20, 1047-1053.
Yan, K., Cao, Q., Reilly, C. M., Young, N. L., Garcia, B. A. and Mishra, N. (2011).
Histone deacetylase 9 deficiency protects against effector T cell-mediated
systemic autoimmunity. J. Biol. Chem. 286, 28833-28843.
Yang, X.-J. and Seto, E. (2008). The Rpd3/Hda1 family of lysine deacetylases: from
bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9, 206-218.
Yim, H. (2013). Current clinical trials with polo-like kinase 1 inhibitors in solid tumors.
Anticancer Drugs Biol. 24, 999-1006.
Ying, C. Y., Dominguez-Sola, D., Fabi, M., Lorenz, I. C., Hussein, S., Bansal, M.,
Califano, A., Pasqualucci, L., Basso, K. and Dalla-Favera, R. (2013). MEF2B
mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B
cell lymphoma. Nat. Immunol. 14, 1084-1092.
Zhao, Y. X., Wang, Y. S., Cai, Q. Q., Wang, J. Q. and Yao, W. T. (2015). Up-
regulation of HDAC9 promotes cell proliferation through suppressing p53
transcription in osteosarcoma. Int. J. Clin. Exp. Med. 8, 11818-11823.
Zhu, D., Oscier, D. G. and Stevenson, F. K. (1995). Splenic lymphoma with villous
lymphocytes involves B cells with extensively mutated Ig heavy chain variable
region genes. Blood 85, 1603-1607.
1495
RESEARCH ARTICLE Disease Models & Mechanisms (2016) 9, 1483-1495 doi:10.1242/dmm.023366
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
